Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Active TB is the fastest growing sector, North America is the largest market

The global anti-tuberculosis therapeutics market is projected to expand significantly, from USD 1.41 billion in 2025 to USD 1.99 billion by 2031, achieving a compound annual growth rate of 5.94%. These therapeutics are essential pharmacological interventions designed to combat infections caused by Mycobacterium tuberculosis. This market's expansion is fundamentally propelled by the rising incidence of tuberculosis, particularly in areas with a high disease burden, alongside the urgent need for advanced treatment protocols to combat multi-drug resistant strains. Furthermore, strong government initiatives and international financial support aimed at improving global diagnosis and treatment accessibility are bolstering this demand. The World Health Organization's Global Tuberculosis Report 2024 highlighted the gravity of this situation, reporting that approximately 10.8 million people contracted tuberculosis in 2023, emphasizing the continuous and pressing demand for efficacious therapeutic solutions.

A primary obstacle to the market's growth is the increasing spread of antimicrobial resistance, which diminishes the effectiveness of conventional first-line antibiotics. The rise of these resistant bacterial strains compels healthcare professionals to employ second-line therapies, which typically involve higher expenses, greater toxicity, and longer treatment periods. Such characteristics often result in decreased patient compliance and impose considerable financial stress on public health infrastructures, consequently hindering the widespread adoption of existing therapeutic alternatives.

Market Drivers

The significant prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis is a key driver for market expansion, demanding the use of sophisticated pharmacological agents beyond standard first-line treatments. When isoniazid and rifampicin prove ineffective, healthcare systems are prompted to acquire second-line therapeutics and innovative combinations, such as BPaL (bedaquiline, pretomanid, and linezolid), to enhance patient recovery. The World Health Organization's 'Global Tuberculosis Report 2024' (October 2024) indicated that approximately 400,000 individuals developed MDR or rifampicin-resistant tuberculosis in 2023. This critical need specifically stimulates the commercial focus on high-value, patent-protected drugs that can reduce treatment times and lessen the severe toxicities associated with older drug categories, thereby redefining revenue opportunities for companies targeting resistant strains.

Growing financial investments from both governmental and non-governmental organizations are accelerating the clinical progress of new anti-tubercular drugs and vaccines. This capital inflow diminishes the financial risks for pharmaceutical companies, nurturing a stronger pipeline of potential therapies aimed at complex infection types. The '2024 Report on TB Research Funding Trends' (December 2024) by the Stop TB Partnership and Treatment Action Group revealed that global funding for tuberculosis research and development reached US$1.2 billion in 2023. Such investments are vital for expanding manufacturing and distribution capacities to satisfy worldwide demand. Highlighting the extensive therapeutic requirement, the World Health Organization reported in 2024 that 8.2 million people were newly diagnosed with tuberculosis in 2023, marking the highest figure recorded since global monitoring began.

Market Challenges

The rising prevalence of antimicrobial resistance (AMR) poses a significant impediment to the expansion of the global anti-tuberculosis therapeutics market. As Mycobacterium tuberculosis strains increasingly resist standard first-line antibiotics, healthcare providers must turn to second-line pharmacological treatments. These alternative therapies come with substantially higher acquisition costs and more pronounced toxicity profiles than conventional treatments. As a result, this heightened financial burden severely strains public health budgets, especially in regions heavily affected by tuberculosis, restricting government programs' capacity to procure and distribute these vital medications broadly. This economic pressure, coupled with side effects that deter patient adherence, directly limits the wider commercial uptake and volume of advanced therapeutic agents.

A notable gap exists between the urgent demand for resistance-specific therapies and their actual implementation, as evidenced by recent figures. The World Health Organization reported in 2025 that only approximately two out of five individuals diagnosed with multidrug-resistant tuberculosis received the required treatment in 2024. This statistic highlights a major market constraint: despite the existence of effective second-line therapeutics, the complexities and resource demands involved in managing resistant strains prevent these products from reaching a substantial portion of the patient population needing them, thus hindering the market's potential for growth.

Market Trends

The widespread integration of BPaL and BPaLM treatment protocols is swiftly transforming the global standard of care, moving away from extended injectable regimens towards more efficient, six-month, all-oral courses. This significant operational shift enables national health systems to centralize their therapeutic supplies around bedaquiline, pretomanid, and linezolid, thereby considerably simplifying supply chain management and boosting treatment completion rates due to easier administration. The rapid pace of this implementation is redefining market demand, as demonstrated by the speed of international purchases. According to the '2024 Annual Report' by TB Alliance (January 2025), over 100,000 courses of the BPaL/M regimen were ordered across nearly 100 countries in 2024, marking the quickest therapeutic deployment in the modern history of the sector.

Concurrently, the creation of pediatric-specific dispersible drug formulations is fostering a distinct market segment dedicated to precise, child-friendly dosing. Manufacturers are progressively shifting from using fragmented adult tablets to developing pleasant, water-soluble options that guarantee accurate bioavailability for children. This emphasis on innovative formulations addresses crucial deficiencies in therapeutic adherence and safety for younger patients. Illustrating the effectiveness of these focused development efforts, interim data from the 'IMPAACT 2034' study, as reported by TB Alliance in a November 2025 press release, showed that a single dose of a novel pediatric dispersible pretomanid formulation produced pharmacokinetic exposures in children similar to those observed in adults.

Key Market Players

• AstraZeneca Plc.
• Johnson & Johnson Private Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.

Report Scope

In this report, the Global Anti-Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Tuberculosis Therapeutics Market, by Disease Type:

• Active TB
• Latent TB
• Others

Anti-Tuberculosis Therapeutics Market, by Diagnosis and Treatment:

• Diagnosis
• Treatment
• others

Anti-Tuberculosis Therapeutics Market, by End User:

• Hospitals
• Specialty Clinics
• Homecare
• others

Anti-Tuberculosis Therapeutics Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Tuberculosis Therapeutics Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.